FMP
EURONEXT
Inactive Equity
Pherecydes Pharma SA develops antibacterial treatments based on the use of bacteriophage viruses or phages. It develops a portfolio of therapeutics, such as anti-Staphylococcus aureusphages for the treatment of bone/joint and diabetic foot ulcer infections; anti-Pseudomonas aeruginosa phages for the treatment of complicated urinary tract infections; and anti-Escherichia coli phages for the treatment of respiratory tract infections. The company was founded in 2006 and is based in Romainville, France.
2 EUR
-0.01 (-0.5%)